Truscreen Group (NZSE:TRU) FCF Margin % : -88.97% (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Truscreen Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Truscreen Group's Free Cash Flow for the six months ended in Sep. 2024 was NZ$-0.92 Mil. Truscreen Group's Revenue for the six months ended in Sep. 2024 was NZ$1.03 Mil. Therefore, Truscreen Group's FCF Margin % for the quarter that ended in Sep. 2024 was -88.97%.

As of today, Truscreen Group's current FCF Yield % is -11.68%.

The historical rank and industry rank for Truscreen Group's FCF Margin % or its related term are showing as below:

NZSE:TRU' s FCF Margin % Range Over the Past 10 Years
Min: -580.72 Med: -158.75 Max: -71.95
Current: -71.95

During the past 10 years, the highest FCF Margin % of Truscreen Group was -71.95%. The lowest was -580.72%. And the median was -158.75%.

NZSE:TRU's FCF Margin % is ranked worse than
76.24% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: -4.42 vs NZSE:TRU: -71.95

Truscreen Group FCF Margin % Historical Data

The historical data trend for Truscreen Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Truscreen Group FCF Margin % Chart

Truscreen Group Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Margin %

Get a 7-Day Free Trial

-126.86

-201.85

-151.07

-134.94

-96.44

Truscreen Group Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-164.32	-105.96	-142.23	-56.28	-88.97

Competitive Comparison of Truscreen Group's FCF Margin %

For the Medical Devices subindustry, Truscreen Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Truscreen Group's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Truscreen Group's FCF Margin % falls into.

Truscreen Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Truscreen Group's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	-2.033	/	2.108
	=	-96.44 %

Truscreen Group's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.92	/	1.034
	=	-88.97 %

Truscreen Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Truscreen Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Truscreen Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (NZSE:TRU) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

TRU:Australia

Address

C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010

Website

https://www.truscreen.com

Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.